FDA
-
-
-
-
-
-
-
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
-
-
-
-
-
-
-
Delcath Systems to Host First Quarter 2026 Earnings Call
-
-
-
-
-
-
-
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
-
-
-
-
-
-
-
Delcath announces study showing 29-month survival for liver cancer treatment
-
-
-
-
-
-
-
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
-
-
-
-
-
-
-
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
-
-
-
-
-
-
-
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
-
334,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


